Bristol Vanlev Settlement Does Not Include Pre-Marketing Results Disclosure
Executive Summary
A settlement over allegations that Bristol-Myers Squibb misled investors about its investigational antihypertensive Vanlev does not establish disclosure guidelines for investigational products